Moleculin Biotech, Inc. MBRX
As ofNov 20, 2026, 3:32 PM EST
- YTD
- +133.38%
- 1 year
- -26.78%
5D +0.06 (+0.76%)
- Market cap
- 8.11M
- EPS (ttm)
- 179.60
- Shares out
- 3.19M
- P/E ratio
- 0.04
- Forward P/E
- -0.29
- YTD return
- +133.38%
- 1-year return
- -26.78%
- Volume
- 44.67K
- Avg volume
- 44.13K
- Open
- 7.96
- Previous close
- 7.93
- Day's range
- 7.57 – 8.18
- 52-week range
- 3.22 – 222.50
- Price target
- 18.00 (+133.0%)
Key statistics
- 50-day average
- 2.49
- 200-day average
- 3.26
- Enterprise value
- -4.00M
- Price / book
- 0.52
- Free cash flow
- -13.24M
- Total cash
- 9.40M
- Total debt
- 390.00K
- Return on equity
- -141.49%
- Short % of float
- 0.71%
Fundamental scorecard
5 of 25 checks passed on MBRX’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -2.44 | -2.09 | +0.35 | +14.34% |
| Aug 13, 2024 | Jun 1, 2024 | -2.10 | -2.23 | -0.13 | -6.19% |
| May 10, 2024 | Mar 1, 2024 | -3.59 | -2.02 | +1.57 | +43.73% |
| Mar 22, 2024 | Dec 1, 2023 | -3.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -3.15 | -2.85 | +0.30 | +9.52% |
| Aug 11, 2023 | Jun 1, 2023 | -4.20 | -3.00 | +1.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | Maxim Group | main | Buy | Buy |
| Apr 12, 2024 | Roth MKM | main | Buy | Buy |
| Mar 26, 2024 | Maxim Group | main | Buy | Buy |
| Dec 14, 2023 | HC Wainwright & Co. | init | — | Buy |
| Apr 18, 2023 | Roth MKM | main | — | Buy |
| Mar 24, 2023 | Oppenheimer | reit | — | Outperform |
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- moleculin.com
News
Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance Moleculin Biotech Completes Treatment Of All 90 Patients In Part A Of Pivotal Phase 2/3 MIRACLE Trial For Annamycin In Relapsed/Refractory AML; Comprehensive Data Expected In Q1 2027, With Part B Planned To Begin In H1 2027
Moleculin Biotech Q3 EPS $(9.59) Misses $(8.53) Estimate
Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout Moleculin Biotech And University Of Texas Receive Australian Patent Covering The Preparation Of Preliposomal Annamycin Lyophilizate
Moleculin Biotech Reports Preclinical Data Showing Annamycin Plus PD-1 Blockade Extends Survival in Pancreatic Cancer Models
Moleculin Reports 43% And 36% Complete Remission Rates In Annamycin Phase 2/3 Trial For Relapsed Or Refractory AML
Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia
12 Health Care Stocks Moving In Tuesday's Intraday Session
Your note
Sign in to keep a note on MBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FOSTER JONATHAN P. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 11,363 |
| GEORGE ROBERT E | Director | Purchase | Dec 25, 2023 | 14,660 |
| KLEMP WALTER V | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2024 | 57,035 |
| PICKER DONALD H | Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 8,001 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.09% | 290,000 | 501.70K | Sep 29, 2024 |
| Vanguard Group Inc | 2.24% | 71,403 | 123.53K | Sep 29, 2024 |
| LPL Financial LLC | 1.13% | 36,103 | 62.46K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 21,818 | 37.74K | Sep 29, 2024 |
| Blackrock Inc. | 0.39% | 12,475 | 21.58K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.34% | 10,996 | 19.02K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.33% | 42,468 | 73.47K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.95% | 30,314 | 52.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 14,790 | 25.59K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 3,218 | 5.57K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 2,055 | 3.56K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,039 | 1.80K | Oct 30, 2024 |
